Seeking Alpha

Jazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of...

Jazz Pharmaceuticals (JAZZ) clocks a 14.7% gain after reporting Q2 revenue and adjusted EPS of $64.6M (+60%) and $0.82, beating a consensus of $61.9M and $0.77. Sales of its flagship Xyrem drug for treating cataplexy rose 67% Y/Y. The company now expects 2011 adjusted EPS of $3.15-$3.25, ahead of a $3.07 consensus. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector